10-Q · October 31, 2025
AptarGroup reported Q3 net sales of $961,131,000 and diluted EPS of $1.92 for the three months ended September 30, 2025, with net income attributable to AptarGroup of $127,927,000 (up from $100,039,000 a year earlier).…
Earnings analysis · 10-Q
ATR earnings analysis
Filed May 1, 2026 · Our reading of the company's report
The latest report
AptarGroup reported strong Q1 2026 earnings with a revenue of $982.9 million, surpassing estimates of $957.6 million, and an adjusted EPS of $1.19, exceeding expectations of $1.15. However, net income saw an 8% decline…
Read full summary
AptarGroup reported strong Q1 2026 earnings with a revenue of $982.9 million, surpassing estimates of $957.6 million, and an adjusted EPS of $1.19, exceeding expectations of $1.15. However, net income saw an 8% decline to $72.7 million compared to last year due to increased costs and a challenging product mix, particularly in the Pharma segment which faced lower sales of higher-margin products. The company anticipates Q2 EPS guidance between $1.32 and $1.40, reflecting a robust growth outlook despite headwinds from supply chain uncertainties.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $1.19
- Segment
- Pharma
- Segment
- Beauty
- Segment
- Closures
What stood out
-
Revenue Growth Exceeds Estimates
Revenue increased 11% YoY to $982.9 million, surpassing estimates by 2.6%.
-
EPS Beat Expectations
Diluted EPS rose to $1.19, beating the estimated EPS of $1.15 by 3.5%.
-
Strong Performance in Beauty Segment
Beauty segment revenue grew 19% YoY to $363.6 million, aided by strong demand.
-
Operating Cash Flow Improvement
Net cash provided by operations increased to $118.7 million from $82.7 million YoY.
-
Free Cash Flow Nearly Doubled
Free cash flow rose to $53.3 million from $25.9 million in the previous period.
-
Q2 EPS Guidance Provided
Management expects Q2 EPS to be in the range of $1.32 to $1.40.
What to watch
-
Increased Costs in Pharma Segment
Pharma operating income margin fell to 33.3%, down from 34.8% due to lower sales of higher-margin products.
-
Interest Expense Rise
Interest expense increased to $16.9 million, up from $11.4 million Year-over-Year.
-
Potential Supply Chain Disruptions
Uncertainties from geopolitical conditions could negatively impact operations and margins.
Management's outlook
EPS guidance for Q2 2026 provided as $1.32 to $1.40, reflecting positive outlook.
Earlier filings 4
10-Q · May 2, 2025
Aptar reported Q1 2025 net sales of $887.3M, down $28.1M (-3.1%) versus Q1 2024, while operating income ticked up to $113.4M (+$1.4M). Gross margin remained near 37.9% and diluted EPS was $1.17 (down from $1.23).…
10-Q · July 26, 2024
Aptar reported Q2 net sales of $910,063,000 and diluted EPS of $1.34 for the three months ended June 30, 2024. Revenue was up modestly versus Q2 2023 (+$14,157,000) while gross margin expanded to ~37.7% and operating…
10-Q · April 28, 2023
Aptar reported Q1 net sales of $860,067,000, up $15,135,000 (+1.8%) versus Q1 2022, while diluted EPS fell to $0.82 from $0.93 a year ago. Gross profit was $302,645,000 (≈35.2% gross margin) and operating income…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.